$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Chronic pain is one of the most debilitating complications following major limb amputation, affecting up to 70% of patients1,2,3. Conventional pain management strategies such as pharmacological interventions, physical therapy, nerve blocks, and psychological therapies often provide limited or transient relief4. Thus, there remains a significant clinical need for effective long-term pain management strategies.
Targeted muscle reinnervation (TMR), initially developed to enhance control of myoelectric prostheses, has emerged as a promising approach to alleviate pain following limb amputation5. The surgical technique involves redirecting transected mixed motor-sensory nerves to nearby motor branches. Clinically, TMR has shown substantial reductions in phantom limb pain, residual limb pain, and neuroma-related symptoms6,7,8. Regenerative peripheral nerve interfaces (RPNI) are another surgical intervention used for nerve injury and amputation-related pain. Amputated nerve ends are sewn to and then wrapped in a free (denervated, avascular) muscle graft9. The amputated axons neurotize the denervated neuromuscular junctions to create muscle contraction in the graft that can be used to create a signal for myoprosthesis control. In contrast to TMR, RPNI has been extensively studied in a rodent model. Similar to TMR, RPNI has been shown to prevent neuroma formation and reduce pain associated with nerve transection injury10,11. Clinically, RPNI has been shown to reduce both phantom and residual limb pain in amputees12.
Despite clinical adoption, the biological mechanisms underlying the analgesic effects of TMR and RPNI remain poorly understood. Preclinical models are crucial for elucidating these mechanisms. Prior work has utilized nerve transection models with modification to superficialize the nerve to directly test for neuroma pain10,11. These models can quantify neuromatous pain with direct stimulation and neuropathic pain by assessing spinal reflex behaviors in the intact nerve distribution remaining in the foot. The spared nerve injury, for example, maintains the sural nerve, and the tibial and common peroneal nerves are transected. Pain behavior testing is performed on the lateral foot13. The hindlimb amputation model represents the most severe possible injury to the limb. As such, there is widespread neuronal loss and the significant inflammatory and healing demands associated with an injury of that nature. When there is a nerve injury, the healthy neurons in the DRG help maintain the injured neurons. With amputation, the population of available healthy neurons is greatly reduced, and for each injured nerve, there is greater neuronal loss than if only a single nerve had been injured14,15,16. Prior reports of rodent hindlimb amputation survival surgery are rare17,18. However, there are advantages versus an upper limb amputation, such as the abundance of historical data examining pain and regeneration related to the sciatic nerve, as well as multiple ambulatory behavioral tests19,20.
To address this gap, we recently developed a rat hindlimb amputation model incorporating immediate TMR (Figure 1). The technique for RPNI creation has been previously published and can be adapted to the hindlimb amputation model21. This model closely mirrors clinical procedures, allowing us to evaluate various pain behaviors, neuroma formation, and neuron preservation (Figure 2)22. Our work has demonstrated significant analgesic benefits to TMR over standard amputation, neuroma prevention, and demonstrated sexually dimorphic responses in cold sensitivity22,23.
The protocol presented here provides a detailed, standardized visual demonstration of the surgical technique, ensuring reproducibility and consistency in experimental approaches. By clearly illustrating key steps, including nerve isolation, precise transection, and tension-free nerve coaptation, this protocol offers researchers a robust framework for investigating the mechanisms underlying TMR-mediated analgesia and neuroma prevention.